Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases.
FAIL · Does not pass the screen
4.06 USD
Price as of 6 Nov 2026Daily close, not a live quote
Screened 2026-11-06 · the tape above runs as of 20:08 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price4.06 USD at the 6 Nov 2026 close
Fair valueUnder review: our model's value is 2.09x the price, above our 2.00x limit.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price4.06 USD
Fair valueUnder review
Ethical score70.0/100
Our investment reviews on this name
2026-11-01Read Accumulation3.96+2.5% to today ✓Markdown gives way to Accumulation after a 5% slide in 3 weeks
2026-10-11Read Markdown4.17-2.6% to today ✓Accumulation gives way to Markdown
2026-10-02Read Accumulation4.17-2.6% to today Markup gives way to Accumulation after a 12% rise in 6 weeks
2026-08-24Read Markup3.71+9.4% to today ✓Accumulation gives way to Markup after an 11% slide in 8 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
CAMP4 Therapeutics Corp holds its Accumulation at $4.06. Consolidating, no directional conviction, held for 34 days.
As held on the ledger · 2026-11-06
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 34 days
Price at the screen
$4.06
Valuation
N/A trailing · -4.77 forward price to earnings
Values screen
FAIL· score 70.0
The Workings
Five Screens, Shown in Full
Does not pass. Accounts receivable
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
1.68%
Below 33%
Interest-bearing debt is just 1.7% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
93.09%
Below 49%
Money owed to the company is 93.1% of assets, above the 49% limit.
Fail
Revenue purity
62.15%
Below 5%
62.1% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
CAMP4 Therapeutics's business is fine, but its receivables are about 93% of its assets, well over the ~49% line, so it does not pass on the financial screens.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when CAMP's ethical verdict changes
Today CAMP does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Fair value under review. Our model's value is 2.09x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
CAMP trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 14.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are up 149%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (6 analysts) rates it strong buy, with a mean price target of $9.
2026-10-25Markdown$3.45-17.3%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 17.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are up 149%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (6 analysts) rates it strong buy, with a mean price target of $9.
2026-10-11Markdown · changed$4.17+0.0%Entry 7
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 4% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 149%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (6 analysts) rates it strong buy, with a mean price target of $9.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 12.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 4% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 149%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (6 analysts) rates it strong buy, with a mean price target of $9.
2026-08-24Markup · changed$3.71+0.0%Entry 5
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 4% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 149%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (6 analysts) rates it strong buy, with a mean price target of $9.
2026-07-24Accumulation$3.71-11.5%Entry 4
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 11.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 4% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 149%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (6 analysts) rates it strong buy, with a mean price target of $9.
2026-07-18Accumulation$4.19+0.0%Entry 3
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 4% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 149%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (6 analysts) rates it strong buy, with a mean price target of $9.
2026-07-03Accumulation$4.19+0.0%Entry 2
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Accumulation$4.19Entry 1
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.